Strategist-Frontline is set to begin, as the company reports first-line velzatinib data at ASCO.

Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.

Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.

A 14% ORR with IDRX-42 in fourth-line GIST looks better than the 9% previously seen with Qinlock.